Pamela Doty
Overview
Explore the profile of Pamela Doty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
673
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doty P
J Gerontol Soc Work
. 2021 Jan;
64(1):78-87.
PMID: 33402055
The author reminisces about her collegial relationships and friendship with Rosalie Kane over a span of nearly 40 years. She also reflects on the main themes of Rosalie's scholarly work...
2.
Schoedel K, Andreas J, Doty P, Eckhardt K, Sellers E
J Clin Psychopharmacol
. 2017 Sep;
37(6):675-683.
PMID: 28926353
Purpose: This phase 1, randomized, double-blind, placebo- and active comparator-controlled crossover study assessed the abuse potential of the antiepileptic drug, lacosamide. Methods: After a qualification phase, 38 healthy, recreational central...
3.
Baulac M, Coulbaut S, Doty P, McShea C, De Backer M, Bartolomei F, et al.
Epileptic Disord
. 2017 Jun;
19(2):186-194.
PMID: 28597842
To evaluate the safety and effectiveness of lacosamide in a real-life setting with the use of a flexible dose titration schedule and individualised maintenance doses up to the maximum approved...
4.
Janus A, Doty P
Gerontologist
. 2017 Jun;
58(5):863-871.
PMID: 28591784
Background And Objectives: We examine trends in informal care from the perspective of both community-dwelling disabled older Americans and their caregivers from 1982 to 2012. We decompose hours of care...
5.
Nadash P, Doty P, von Schwanenflugel M
Gerontologist
. 2017 Apr;
58(3):588-597.
PMID: 28379357
Background And Objectives: Since 1995, Germany has operated one of the longest-running public programs providing universal support for the cost of long term services and supports (LTSS). Its self-funding, social...
6.
Wechsler R, Yates S, Messenheimer J, Leroy R, Beller C, Doty P
Epilepsy Res
. 2017 Jan;
130:13-20.
PMID: 28086164
Objective: Assess the safety of adjunctive lacosamide for the treatment of uncontrolled primary generalized tonic-clonic seizures in patients (16-65 years) with primary generalized (genetic) epilepsy (PGE). Methods: An open-label pilot...
7.
Steinhoff B, Eckhardt K, Doty P, De Backer M, Brunnert M, Schulze-Bonhage A
Epilepsy Behav
. 2016 Apr;
58:35-43.
PMID: 27054272
This noninterventional, observational, postauthorization safety study (SP0942, NCT00771927) evaluated the incidence of predefined cardiovascular- (CV) and psychiatric-related treatment-emergent adverse events (TEAEs), in patients with epilepsy and uncontrolled partial-onset seizures, when...
8.
Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain N
Epilepsy Behav
. 2015 Sep;
52(Pt A):119-27.
PMID: 26414341
Objective: The objective of this study was to describe a priori protocol-defined analyses to evaluate the safety and tolerability of adjunctive oral lacosamide (200-600 mg/day) in adults (ages 16-70 years)...
9.
Doty P, Nadash P, Racco N
Milbank Q
. 2015 Jun;
93(2):359-91.
PMID: 26044633
Unlabelled: POLICY POINTS: France's model of third-party coverage for long-term services and supports (LTSS) combines a steeply income-adjusted universal public program for people 60 or older with voluntary supplemental private...
10.
Rosenfeld W, Fountain N, Kaubrys G, Ben-Menachem E, McShea C, Isojarvi J, et al.
Epilepsy Behav
. 2014 Dec;
41:164-70.
PMID: 25461210
Long-term (up to 8 years of exposure) safety and efficacy of the antiepileptic drug lacosamide was evaluated in this open-label extension trial (SP615 [ClinicalTrials.gov identifier: NCT00552305]). Patients were enrolled following...